Search

everythinglearnresearchcommunity

for

Search:↓

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

Trying out a new exosome treatment for male pattern baldness, in addition to increasing vitamin intake and using existing treatments such as Nizoral and scalp drops. The user has no expectations that the new treatment will work but is giving it a try anyway.

The user has been using a daily capsule containing 1mg finasteride and 2.5mg minoxidil for 11 months, with noticeable regrowth on the crown but minimal improvement on the hairline. They experienced no significant side effects and plan to continue the treatment long-term.

The conversation discusses the best carrier for RU58841, comparing Ethanol and PEG400. The user seeks advice on which carrier is more effective.

A user shared their year-long hair loss treatment using minoxidil, microneedling, and scalp massages, reporting moderate hair growth and stabilization. They suggest starting early with less harmful methods and consider adding finasteride or dutasteride if needed.

User seeks KX-826 anti-androgen product and asks for purchase suggestions and experiences. Dave-8D recommends buying powder from the same website and making a topical solution, mentioning possible high dosage from Minoxidil max causing side effects.

The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.

Fatty acid metabolic signaling can activate epithelial stem cells for hair regeneration. Oleic and palmitoleic acids showed the best results, but practical application on humans remains uncertain.

A user proposed genetically engineering scalp stem cells to stop androgen receptors from causing hair loss. Others discussed the feasibility, existing research, and potential issues with this approach, including targeting the correct cells and unintended effects.

The conversation is about a person's hair improvement after 14.5 months using RU58841 and Minoxidil topically at 50 mg each day, with noticeable hairline improvement but incomplete crown area recovery. The person struggles to take good pictures of their crown area.

The user shared their 11-year journey battling hair loss, highlighting the importance of consistent treatment and avoiding common mistakes. Treatments included minoxidil, finasteride, derma rolling, ketoconazole, multivitamins, and a hair transplant.

A male in his early 20s with CCCA (scarring alopecia) started treatment with Finasteride, Fluocinolone, and Doxycycline. Steroid injections were suggested but not yet done.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.

A woman experienced hair regrowth after using self-prescribed finasteride and dutasteride from online sources, despite doctors' reluctance to prescribe these due to potential birth defects. Her dermatologist acknowledged the effectiveness of these treatments and advised her to continue using them while avoiding pregnancy.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

A user reported that taking 20mg copper and 200mcg selenium completely stopped their hair loss. The conversation is about hair loss treatments.

A 40-year-old shared their positive experience with a second hair transplant at HDC Cyprus, involving 4148 grafts and costing around 9,000 euros. They used oral minoxidil, Dutasteride, biotin, and vitamins to aid recovery and were pleased with the results.

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

Users discuss waiting for new hair loss treatments and share struggles with side effects from current options like Minoxidil and Finasteride. They express hope for Pyrilutamide and CosmeRNA to provide better solutions.

A user is experiencing facial bloating from low-dose topical finasteride due to high estradiol levels and is seeking advice on using DIM to manage this issue, including dosage and brand recommendations.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841, and highlights hair multiplication research from Koehler Lab at Harvard. Users express optimism about future advancements.

A female user has experienced severe hair shedding since stopping birth control in late 2022, diagnosed as telogen effluvium with no signs of androgenetic alopecia. Despite healthy living and optimal bloodwork, she continues to shed hair daily but also sees significant regrowth.

The conversation discusses using a violet ray device for hair regrowth, citing a case where zinc ion treatments showed promising results. It also mentions similar devices like the Growcombr and niostem helmet.

Exploring potential treatments for hair loss, such as Minoxidil, Finasteride, RU58841 and Pyrilutamide. The user is looking for feedback on whether KX-826 can be used successfully as a single therapy to stop the miniaturization process.

The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.

The conversation discusses the safety and trustworthiness of ordering RU58841 from Lyphar Biotech in China, with a focus on pricing and reliability. The user is seeking advice on whether to proceed with the purchase or consider alternative sources.

User shared 13 months of progress using finasteride, microneedling, vitamins, and scalp care, and recently started stemoxydine. The post includes before and after photos.

A user shared their one-year hair loss treatment progress using oral finasteride, topical finasteride/minoxidil, and microneedling, reporting no current side effects and significant hair improvement. They also use Head & Shoulders for dandruff control and recommend consistency in treatment.

A user who was part of an ongoing trial for a prolactin blocker and had regrowth, but the progress photos were not shared due to negative reactions from other users. Treatments mentioned include HMI-115, Minoxidil, Finasteride, and RU58841.